Cite
HARVARD Citation
Hirbe, A. et al. (2020). A phase II study of pazopanib as front-line therapy in patients with non-resectable or metastatic soft-tissue sarcomas who are not candidates for chemotherapy. European journal of cancer. pp. 1-9. [Online].